You are here: Industry Insights > Sosei Heptares

News List

Sosei Heptares and Verily to collaborate on immune-mediated disease treatments pharmatimes
January 06, 2022
The companies share the goal of furthering knowledge around GPCR biology in immune cells in order to better understand a range of immune system disorders.
Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19 AmericanPharmaceuticalReview
December 09, 2021
Sosei Group Corporation announced it has received grant funding from Wellcome, through the COVID-19 Therapeutics Accelerator. The funding will be used to advance the pre-clinical development of the Company's novel oral anti-viral small molecules ...
University of Glasgow reveals drug design for new Alzheimer’s treatments PharmaTimes
December 01, 2021
A team of scientists and pharmaceutical collaborators have discovered a ‘bench to bedside’ drug design, which will hopefully improve the future treatment of Alzheimer’s disease...
Sosei Heptares and GSK sign collaboration and license pact targeting GI immune disorders expresspharma
December 22, 2020
Sosei Heptares to get an upfront payment, research funding and potential near-term development milestones of up to £34 million ($44 million), potential downstream payments of up to £336 million ($437 million) and tiered royalties.
Sosei Heptares' COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules americanpharmaceuticalreview
December 07, 2020
Sosei announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19.
Sosei Heptares’ COVID-19 programme advances promising molecules pharmatimes
November 23, 2020
Japanese pharma company Sosei Heptares has identified and advanced the ‘most promising’ molecules in its COVID-19 research and development programme.
Sosei Heptares scores $5m milestone payment from Pfizer pharmatimes
October 09, 2020
Sosei Heptares has received a $5m milestone payment from its strategic alliance partner Pfizer after the first subject in a clinical trial was dosed with a new drug candidate from the collaboration between the two companies.
Sosei Heptares Announces Nomination of a Third Clinical Candidate by Pfizer from Multi-target Drug Discovery Collaboration firstwordpharma
December 24, 2019
Sosei Group Corporation ("the Company"; TSE: 4565) has been notified by its strategic alliance partner Pfizer that it has nominated a third clinical candidate from the multi-target drug discovery collaboration between the two companies.
Sosei Heptares Announces Clinical Start of Drug Discovery Collaboration with Pfizer americanpharmaceuticalreview
December 24, 2019
Sosei Group has been notified by its strategic alliance partner Pfizer that it has dosed the first subject in a clinical trial with a new drug candidate nominated from the multi-target drug ...
Sosei Heptares, Takeda Announce Partnership americanpharmaceuticalreview
August 07, 2019
Sosei Heptares has entered into a strategic multi-target partnership with Takeda Pharmaceutical to discover, develop and commercialize novel molecules, including small molecules and biologics that modulate G protein-coupled receptor (GPCR) targets.

Previous page 1 2 Next page